Significantly improving treatment outcomes for patients with cancer by applying phosphoramidite chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. (NASDAQ: NCNA)
Total raised: $10.52648M
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 29.11.2011 | Series A | $10.52648M | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 28.09.2017 | Term Sheet... | DIAL UP THE DRAMA Good mornin... | - | - | fortune.co... |
| 19.09.2017 | Term Sheet... | VCs VERSUS ICOs Companies hav... | - | - | fortune.co... |
| 05.09.2017 | Term Sheet... | CATCH UP Good morning, Term S... | - | - | fortune.co... |
| 29.11.2011 | NuCana Bio... | NuCana BioMed, an Edinburgh UK... | funding U... | - | finsmes.co... |